Y-Intercept (HK)
CRDF icon

Y-Intercept (HK)’s Cardiff Oncology CRDF Stock Holding History

Y-Intercept (HK)’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-22,388
Closed -$29.1K – 1657
2026
Q2 		$29.1K Buy
+22,388
New +$35.5K ﹤0.01% 1638
2024
Q2 		– Sell
-29,464
Closed -$157K – 1477
2024
Q1 		$157K Buy
+29,464
New +$78.3K 0.01% 1200

Other funds holding CRDF

GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
PRTG
Post Resch Tallon Group Pittsford, New York $146M AUM 18.19% 1-Year Est. Return
Baker Ellis Asset Management
Baker Ellis Asset Management Vancouver, Washington $917M AUM 26.82% 1-Year Est. Return
Capital Advisors Wealth Management
Capital Advisors Wealth Management Yakima, Washington $888M AUM 16.06% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $181M AUM 9.93% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.25B AUM 28.18% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Y-Intercept (HK)'s CRDF Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Cardiff Oncology (CRDF) in Q3 2026, closing a stake of 22,388 shares — an estimated $29.1K sold.

Y-Intercept (HK) first reported a position in CRDF in Q1 2024 and held it in 2 quarters. The position peaked at $157K in Q1 2024. 11 funds tracked by Wall St. Rank hold CRDF as of Q3 2026.

  • Y-Intercept (HK) reported no remaining Cardiff Oncology position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 22,388 Cardiff Oncology shares in Q3 2026, an estimated $29.1K.
  • Y-Intercept (HK) first reported a position in Cardiff Oncology in Q1 2024 and held it in 2 quarters.
  • Y-Intercept (HK)'s Cardiff Oncology position peaked at $157K in Q1 2024.
  • 11 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.